Halozyme Therapeutics, Inc. reiterating its financial guidance for 2022, which was last provided on August 9, 2022 as a result of the close of the Antares Pharma transaction and strong year-to-date results. For the full year 2022, the Company expects: total revenue of $655 million to $685 million, representing growth of 48% to 55% over 2021 total revenue primarily driven by projected revenue contribution from the Antares business of $115 million to $125 million; GAAP operating income of $240 million to $265 million, which includes one-time transaction costs of approximately $45 million and amortization of approximately $80 million related to the Antares acquisition; GAAP net income of $170 million to $195 million; GAAP diluted earnings per share of $1.20 to $1.35 due to acquisition related costs in 2022.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
43.42 USD | +0.61% | +6.78% | +18.05% |
May. 07 | Halozyme Therapeutics Q1 Non-GAAP Earnings, Revenue Rise; 2024 Guidance Reaffirmed | MT |
May. 07 | Transcript : Halozyme Therapeutics, Inc., Q1 2024 Earnings Call, May 07, 2024 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+18.05% | 5.49B | |
+4.84% | 109B | |
+11.06% | 105B | |
-0.38% | 22.25B | |
-11.87% | 22.09B | |
-7.66% | 18.68B | |
-36.52% | 17.58B | |
-10.01% | 16.85B | |
+3.69% | 13.76B | |
+35.92% | 12.46B |
- Stock Market
- Equities
- HALO Stock
- News Halozyme Therapeutics, Inc.
- Halozyme Therapeutics, Inc. Reiterates Financial Guidance for the Year 2022